New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
07:37 EDTAEZSAeterna Zentaris announces first patient treated for Phase 2 trial with AEZS-108
Aeterna Zentaris announced that a first patient has been treated for the randomized Phase 2 trial in chemotherapy refractory triple-negative luteinizing hormone-releasing hormone receptor-positive metastatic breast cancer, with the company's targeted doxorubicin peptide conjugate, AEZS-108.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:34 EDTAEZSAeterna Zentaris adds center to Phase 3 trial in endometrial cancer
Aeterna Zentaris announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. Furthermore, the company announced that patient recruitment for this trial now stands at over 320 patients out of a projected total of 500 patients. Patient recruitment is in line to secure expected interim analysis in H1 2015, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use